Cullinan Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 85
- Market Cap
- $1B
- Introduction
Cullinan Management, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- Conditions
- SjögrenSjogren DiseaseSjogren's Syndrome
- Interventions
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT07041099
- Locations
- 🇺🇸
Cullinan Investigative Site, Plano, Texas, United States
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT06994143
- Locations
- 🇮🇹
Cullinan Investigative Site, Rome, Italy
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06613360
- Locations
- 🇦🇺
Cullinan Investigative Site, Victoria Park, Australia
🇲🇩Arensia Research Clinic, Chisinau, Moldova, Republic of
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06381141
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Levine Cancer Institute, Winston-Salem, North Carolina, United States
🇺🇸Mt. Sinai, New York City, New York, United States
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT06035744
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Orlando Health, Orlando, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
- Prev
- 1
- 2
- Next